October 2026
- Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes
- Statins in Older Adults — Evidence at Last
- Gold Standard Science and Biomedical Research — Principles, Governance, and Scientific Independence
- PML Resolution after Treatment with Virus-Specific T Cells Followed by HCT
- More on NETs in Lupus
- Bilateral Pacing Neuromuscular Prosthesis for Laryngeal Paralysis
- Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma
- Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia
- Thyroglossal Duct Cyst
- Billing for Messaging on the Patient Portal
- Tobacco-Cessation Treatment for Global Impact
- An Echo Unheard
- Giredestrant plus Everolimus in Advanced Breast Cancer
- Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
- Joint Clinical Assessments — A New Chapter in European Pharmaceutical Policy
- The Mayor
- Serotonin Syndrome
- Vaping for Crypto — Smart Devices, Risky Business
- Opioid-Settlement Funds — Lessons from Tobacco
- IARC Perspective on Lung Cancer Screening
- Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
- A Step in the Search for the Elusive Holy Grail of Early Detection of Cancer
- Short or Long Antibiotic Regimens in Orthopedics
- Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
- Reengineering Coagulation with a Bispecific Antibody
- Tozorakimab to Prevent COPD Exacerbations
- Catheter-Directed Thrombolysis in Intermediate-High–Risk Pulmonary Embolism
- Immediate Ambulatory Electrocardiographic Monitoring in Syncope
- Tricuspid-Valve Intervention in Heart Failure
- Timing of PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation
- Pulmonary Denervation for Heart Failure–Related Pulmonary Hypertension
- Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients
- The Emerging Role of Treatment Policy Implementation Trials in Acute Coronary Syndrome
- Prasugrel versus Ticagrelor in Acute Coronary Syndromes
- Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI
- Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event
- Prevalence of Silent Atherosclerosis across Adult Life
- Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults
- Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain
- Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
- Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis
- Eplontersen for Transthyretin Amyloid Cardiomyopathy
- Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310
- Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment
- Andes Virus — A Clinical Review
- Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty
- Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609.
- Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema
- Vasopressors or Fluids in Early Septic Shock
- Obexelimab for the Treatment of IgG4-Related Disease